*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# EPS Creative Health Technology Group Limited

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 3860)

## (1) CHANGE OF DIRECTORS AND CHIEF EXECUTIVE OFFICER; (2) CHANGE OF AUTHORISED REPRESENTATIVE; AND (3) CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces the following changes of Directors, chief officers, LR Authorised Representative and the changes in composition of the Board committees with effect from 2 November 2026:

(1) Mr. Washikita has ceased to be the Chief Executive Officer in order to focus on his roles as an executive Director and the chairman of the Board;

(2) Mr. Miyano has tendered his resignation as an executive Director and the Chief Administrative Officer, and has ceased to be a LR Authorised Representative and a member of the Remuneration Committee;

(3) Mr. Narumi has tendered his resignation as an executive Director and the Chief Financial Officer;

(4) Ms. Du has tendered her resignation as an executive Director and the Chief Technology Officer, and has ceased to be a member of the Nomination Committee;

(5) Mr. Uematsu has tendered his resignation as a non-executive Director, and has ceased to be a member of the Audit Committee;

(6) Mr. Kaku has been appointed as an executive Director, the Chief Executive Officer, a member of each of the Remuneration Committee and the Nomination Committee;

(7) Each of Mr. Zhuang, Mr. Mao and Mr. Ichinose has been appointed as an executive Director;

(8) Mr. Kimura has been appointed as a non-executive Director and a member of the Audit Committee;

(9) Ms. Sun has been appointed as an independent non-executive Director, the chairman of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee;

(10) Mr. Kitagawa has been appointed as a LR Authorised Representative; and

(11) Mr. Chan has been redesignated from a member to the chairman of the Nomination Committee.

## CHANGE OF DIRECTORS AND CHIEF EXECUTIVE OFFICER

Reference is made to the announcement of the Company dated 9 September 2026 (the "**Previous Announcement**") in relation to the disposal (the "**Disposal**") of up to 130,000,000 ordinary shares (the "**Shares**") of the Company by EPS Holdings, Inc. ("**EPS HD**") to Wisdoms Group International Co., Limited ("**Wisdoms Group**") and the potential changes to the composition of the board (the "**Board**") of directors (the "**Director(s)**") and the management of EPS Creative Health Technology Group Limited (the "**Company**", together with its subsidiaries, the "**Group**"). Following discussions regarding the organisation and management of the Group, certain changes of Directors and management of the Company have been proposed. The Board hereby announces the following changes to the composition of the Board and management of the Company.

### Resignation of Directors and Cessation to act as Chief Executive Officer

The Board hereby announces that with effect from 2 November 2026:

(i) Mr. Washikita Kenichiro ("**Mr. Washikita**") has ceased to be the chief executive officer of the Company (the "**Chief Executive Officer**") in order to focus on his roles as an executive Director and the chairman of the Board;

(ii) Mr. Miyano Tsumoru ("**Mr. Miyano**") has tendered his resignation as an executive Director and the chief administrative officer of the Company (the "**Chief Administrative Officer**") in order to focus on his personal and other business engagements;

(iii) Mr. Narumi Shoichi ("**Mr. Narumi**") has tendered his resignation as an executive Director and the chief financial officer of the Company (the "**Chief Financial Officer**") in order to focus on his personal and other business engagements;

(iv) Ms. Du Yao ("**Ms. Du**") has tendered her resignation as an executive Director and the chief technology officer of the Company (the "**Chief Technology Officer**") in order to focus on her personal and other business engagements; and

(v) Mr. Uematsu Takahiro ("**Mr. Uematsu**") has tendered his resignation as a non-executive Director in order to focus on his personal and other business engagements.

Each of Mr. Washikita, Mr. Miyano, Mr. Narumi, Ms. Du and Mr. Uematsu has confirmed that he/she has no disagreement with the Board and that he/she is not aware of any other matters relating to his/her resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board would like to take this opportunity to express its gratitude to Mr. Miyano, Mr. Narumi, Ms. Du and Mr. Uematsu for their valuable efforts and contributions to the Company during their tenure of office with the Company.

**Appointment of Directors and Chief Executive Officer**

The Board is pleased to announce that with effect from 2 November 2026, (i) Mr. Kaku Ken ("**Mr. Kaku**") has been appointed as an executive Director and the Chief Executive Officer; (ii) each of Mr. Zhuang Xiaotong ("**Mr. Zhuang**"), Mr. Mao Ruifeng ("**Mr. Mao**") and Mr. Ichinose Shigekazu ("**Mr. Ichinose**") has been appointed as an executive Director; (iii) Mr. Kimura Toshikatsu ("**Mr. Kimura**") has been appointed as a non-executive Director; and (iv) Ms. Sun Zhuting ("**Ms. Sun**") has been appointed as an independent non-executive Director.

Set out below are the biographical details of the new Directors:

**Mr. Kaku**, aged 44, has over 20 years of experience in cross-border investment and M&A as well as venture capital. He specialises in leveraging the industrial strengths of both China and Japan to create synergies and help portfolio companies enhance their enterprise value.

Mr. Kaku graduated from Waseda University in Japan in 2006 with a degree in law. In May 2017, he founded AIS CAPITAL LIMITED. ("**AIS Capital**"), and has served as its managing partner and chief executive officer ever since. Prior to founding AIS Capital, he joined Marubeni Corporation, one of Japan's five major general trading companies, in April 2006, where he worked in international trade and cross-border mergers and acquisitions. In October 2008, he joined Daiwa SMBC Capital Co., Ltd., where he focused on early-stage investments in technology and innovation companies, as well as the establishment and fundraising for Renminbi ("**RMB**") funds. In November 2009, he was assigned to China as the managing director of a fund management company, where he was responsible for the operations and management of the first Sino-foreign joint venture RMB fund in Central China.

As disclosed in the Previous Announcement, Wisdoms Group, which is wholly owned by Mr. Kaku, entered into an agreement on 9 September 2026 with EPS HD, a controlling shareholder of the Company, in relation to the Disposal, details of which are set out in the Previous Announcement. As at the date of this announcement, Mr. Kaku is interested in 104,000,000 Shares through Wisdoms Group within the meaning of Part XV of the Securities and Futures Ordinance ("**SFO**"). *(Note)* Mr. Kaku had previously served as a consultant of EPS HD. He is also a partner of AIS Capital Partners Limited Liability Partnership, the general partner of BooSTARX Fund No. 1 Limited Partnership*

("**BooSTARX**"). The Group had committed to invest JPY100 million (equivalent to approximately HK$7.1 million) in BooSTARX as a limited partner as disclosed in the announcement of the Company dated 30 August 2021, but such investment was disposed of by the Group to EPS HD in March 2025.

Pursuant to the letter of appointment entered into between the Company and Mr. Kaku, he has been appointed for a term of two years commencing from 2 November 2026 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Kaku is entitled to a monthly salary of HK$153,846 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the remuneration committee of the Board (the "**Remuneration Committee**") and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

**Mr. Zhuang**, aged 43, is the assistant to the chairman and the principal research fellow of the Research Centre of the EPS HD group. Mr. Zhuang joined the EPS HD group in 2022 and has over 20 years of experience in research and development of therapies for diabetes, cell transplantation, and cell regeneration. He is also the founder and a director of Cyber Health Consulting Co., Ltd. He also served as the deputy director of the Joint Institute for Cell Regeneration of Tenth People's Hospital affiliated to Tongji University, and a member of the Precision Medicine Expert Committee of the Shanghai BioPharmaceutics Industry Association, from 2018 to 2020.

Mr. Zhuang obtained a Bachelor of Medicine from Norman Bethune Health Science Centre, Jilin University in China in 2007, and completed a doctoral programme in the Department of Diabetes, Endocrinology and Nutrition at the Graduate School of Medicine, Kyoto University in Japan in 2014.

As at the date of this announcement, Mr. Zhuang is interested in 2,000,000 Shares within the meaning of Part XV of the SFO. *(Note)*

Pursuant to the letter of appointment entered into between the Company and Mr. Zhuang, he has been appointed for a term of two years commencing from 2 November 2026 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Zhuang is entitled to a monthly salary of JPY324,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

**Mr. Mao**, aged 44, is the director in Japan-China Development Department of EP-Bio Partners, Co., Ltd. Mr. Mao joined the EPS HD group in 2012 and has over 15 years of extensive experience in pharmaceutical and clinical development activities across Japan and China, with a strong understanding of the cultural and business environments as well as the characteristics of the pharmaceutical industries in both countries. He also has extensive experience in cross-cultural communication and project coordination. Mr. Mao is currently an executive officer of EP-Bio

Partners Co., Ltd., a member of the EPS HD group, and is also a director of each of Suzhou EPS Tigermed Pharmaceutical Technology Co., Ltd.*, Shanghai EPS Pharmaceutical Development Co., Ltd.* and Beijing Global Pharmaceutical Research Co., Ltd.*, which are subsidiaries of the Company.

Mr. Mao graduated from Shanghai Sanda University in Shanghai, China, majoring in Computer Software in 2004. He also received a bachelor's degree of Economic from Kyushu International University in Kitakyushu, Fukuoka, Japan in 2009.

As at the date of this announcement, Mr. Mao is interested in 4,000,000 Shares within the meaning of Part XV of the SFO. *(Note)*

Pursuant to the letter of appointment entered into between the Company and Mr. Mao, he has been appointed for a term of two years commencing from 2 November 2026 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Mao is entitled to a monthly salary of JPY190,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

**Mr. Ichinose**, aged 60, has over 30 years of experience in the pharmaceutical and healthcare services industry. He worked in Kasho Co., Limited, a life science company, in 1990 and subsequently started working in EPS HD since January 2002 and has been the President of EPS Americas Corp., a wholly owned subsidiary of EPS HD, since January 2017. He is also currently the Representative Director of EP Trading Co., Ltd., a wholly owned subsidiary of the Company. Mr. Ichinose graduated from the Department of Law, Faculty of Law in Kanazawa University in Japan in 1990.

Pursuant to the letter of appointment entered into between the Company and Mr. Ichinose, he has been appointed for a term of two years commencing from 2 November 2026 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Ichinose is entitled to a monthly salary of JPY190,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

**Mr. Kimura**, aged 61, has over 32 years of experience in his career as an economist, conducting research and analysis on the Chinese economy and financial markets. He also worked as management and marketing specialist for an independent asset management company specialising in Japanese stocks.

Mr. Kimura graduated from the Department of Foreign Languages (Japanese major) from Wuhan University, graduated with a Master's Degree from the Graduate School of Education in Fukushima University in Japan in 1991 and completed a doctoral programme at the University of Tsukuba in 1994.

He is currently the managing partner of AIS Capital Limited since 2018. Prior to joining AIS Capital Limited, he worked at Daiwa Research Institute from 1994 to 2010 and joined SMBC Nikko Securities from 2013 to 2018 as a senior economist.

Pursuant to the letter of appointment entered into between the Company and Mr. Kimura, he has been appointed for a term of two years commencing from 2 November 2026 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Kimura is entitled to a monthly salary of JPY190,000 on a 12-month basis, which has been recommended by the Remuneration Committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

**Ms. Sun**, aged 43, is a top Chinese KOL (Key Opinion Leader) based in Japan with years of experience in public relations and marketing for Chinese and Japanese brands. She previously worked in sales and business development at an advertising agency in 2016 to 2025 and has practical experience managing Chinese social media accounts and cross-border e-commerce. She aims to provide the Board with market insights from a consumer perspective, assisting in company growth, enhancing brand trust, and supporting them in fully considering reputational risks in their decision-making processes.

Ms. Sun obtained a Bachelor of Art from Tianjin University of Finance and Economics majoring in International Business in 2005.

Pursuant to the letter of appointment entered into between the Company and Ms. Sun, she has been appointed for a term of two years commencing from 2 November 2026 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Ms. Sun is entitled to a monthly salary of JPY190,000 on a 12-month basis, which has been recommended by the Remuneration Committee and approved by the Board with reference to her qualifications, experience and responsibilities with the Company.

Ms. Sun has confirmed that (i) she met the independence criteria set out in Rule 3.13 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on the Stock Exchange; (ii) she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed above, as at the date of this announcement, each of Mr. Kaku, Mr. Zhuang, Mr. Mao, Mr. Ichinose, Mr. Kimura and Ms. Sun (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the three years prior to the date of this announcement; (iii) does not have any other relationship with any directors, senior management or substantial or controlling shareholders of the Company; and (iv) does not have any interest in the Shares or underlying Shares (within the meaning of Part XV of the SFO).

Save as disclosed above, there is no information in relation to the appointments of Mr. Kaku, Mr. Zhuang, Mr. Mao, Mr. Ichinose, Mr. Kimura and Ms. Sun that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its warmest welcome to Mr. Kaku, Mr. Zhuang, Mr. Mao, Mr. Ichinose, Mr. Kimura and Ms. Sun for their respective appointments.

*Note:* Following completion of the acquisition of 30,000,000 Shares by Wisdoms Group from EPS HD, Wisdoms Group has sold an aggregate of 26,000,000 Shares at HK$0.63 per Share to purchasers approved by EPS HD, namely: (i) 4,000,000 Shares to Mr. Liang Fei; (ii) 4,000,000 Shares to Mr. Mao; (iii) 2,000,000 Shares to Mr. Zhuang; (iv) 4,000,000 Shares to Mr. Kitagawa Rikiya ("**Mr. Kitagawa**"); (v) 2,000,000 Shares to Mr. Xia Xiangming; and (vi) 10,000,000 Shares to Honestar Medical Limited, which is a company ultimately owned as to 97% by Mr. Yan Ping and 3% by Mr. Chiu Chun Tak.

## CHANGE OF AUTHORISED REPRESENTATIVE

Following the resignation of Mr. Miyano, with effect from 2 November 2026, (i) Mr. Miyano has ceased to be the authorised representative of the Company under the Listing Rules ("**LR Authorised Representative**"); and (ii) Mr. Kitagawa, an executive Director, has been appointed as a LR Authorised Representative in place of Mr. Miyano.

## CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the change of Directors, the Board further announces the following changes in composition of the Board committees with effect from 2 November 2026:

(i) **Audit Committee**

Mr. Uematsu has ceased to be a member of the audit committee of the Board (the "**Audit Committee**"), and each of Mr. Kimura and Ms. Sun has been appointed as a member of the Audit Committee.

(ii) **Remuneration Committee**

Mr. Miyano has ceased to be a member of the Remuneration Committee, Ms. Sun has been appointed as the chairman of the Remuneration Committee, and Mr. Kaku has been appointed as a member of the Remuneration Committee.

(iii) **Nomination Committee**

Ms. Du has ceased to be a member of the nomination committee of the Board (the "**Nomination Committee**"), Mr. Chan has been redesignated from a member to the chairman of the Nomination Committee, and each of Mr. Kaku and Ms. Sun has been appointed as a member of the Nomination Committee.

## COMPLIANCE WITH THE LISTING RULES

Reference is made to the announcement of the Company dated 9 October 2026. Following the change of Directors, the Board now comprises seven executive Directors, one non-executive Director and four independent non-executive Directors, and the Company is in compliance with the number and/or composition requirements of the Board, the Audit Committee, the Remuneration Committee and the Nomination Committee under Rules 3.10A, 3.21, 3.25 and 3.27A of the Listing Rules.

By order of the Board
**EPS Creative Health Technology Group Limited**
**Miyano Tsumoru**
*Executive Director*

Hong Kong, 2 November 2026

*As at the date of this announcement, the executive Directors are Mr. Washikita Kenichiro, Mr. Kaku Ken, Mr. Liang Fei, Mr. Kitagawa Rikiya, Mr. Zhuang Xiaotong, Mr. Mao Ruifeng and Mr. Ichinose Shigekazu; the non-executive Director is Mr. Kimura Toshikatsu; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Saito Hironobu, Ms. Zhang Cuiping and Ms. Sun Zhuting.*

* *For identification purpose only*